Differential anti-atherosclerotic effects in the innominate artery and aortic sinus by the liver X receptor agonist T0901317.
Activation of liver X receptors (LXRs) has been reported to reduce atherosclerosis in mouse models. However, this can be associated with enhanced liver de novo lipogenesis and elevation of plasma triglyceride-rich VLDL, which may limit its clinical use. In this study, we administered orally the LXR agonist T0901317 to male LDLR-/- mice fed a Western diet. This induced a persistent enhanced hypertriglyceridemia by largely increasing plasma triglyceride-rich VLDL. T0901317 treatment decreased atherosclerosis with a much more pronounced response and dose dependence in the innominate artery than in the aortic sinus. Lesions in the innominate artery were less complex containing mostly macrophage foam cells in T0901317-treated mice. However, in the aortic root, a significant reduction of atherosclerosis was seen only in the right coronary-related aortic sinus (RC) of T0901317-treated mice. Increasing the dose of T0901317 did not extend atheroprotection to the other sinuses of the aortic root. Lesions in the RC were less complex both in T0901317 and vehicle-treated mice with macrophage foam cells predominating. On the other hand, in T0901317-treated mice, the left coronary-related sinus (LC) lesions while not reduced in size, were more complex with a large fibrous cap and necrotic core, more collagen-positive areas, and variable macrophage foam cell content compared to vehicle-treated mice. These data suggest that activation of LXR by T0901317 had differential anti-atherosclerotic effects in two arterial regions in mice with hypertriglyceridemia.
Peng
Dacheng
D
Ben May Department for Cancer Research, University of Chicago, 929 East 57th Street, Chicago, IL 60637, USA. dpeng@uchicago.edu
Hiipakka
Richard A
RA
Reardon
Catherine A
CA
Getz
Godfrey S
GS
Liao
Shutsung
S
D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy / Q000517:prevention & control*; D016122:Brachiocephalic Trunk / Q000473:pathology*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D005487:Foam Cells / Q000166:cytology; D005786:Gene Expression Regulation; D006845:Hydrocarbons, Fluorinated / Q000494:pharmacology*; D015228:Hypertriglyceridemia / Q000188:drug therapy; D008055:Lipids / Q000737:chemistry; D000071518:Liver X Receptors; D008264:Macrophages / Q000166:cytology / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D057093:Orphan Nuclear Receptors; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D012850:Sinus of Valsalva / Q000473:pathology*; D013449:Sulfonamides / Q000494:pharmacology*; D005466:Fluorocarbons; D000096926:Benzenesulfonamides
D004268:DNA-Binding Proteins; D006845:Hydrocarbons, Fluorinated; D008055:Lipids; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D018160:Receptors, Cytoplasmic and Nuclear; D013449:Sulfonamides; C423915:T0901317; D005466:Fluorocarbons; D000096926:Benzenesulfonamides